Please note that this post contains affiliate links and any sales made through such links will reward MageeNews.com a small commission – at no extra cost to you.
WASHINGTON, D.C. – U.S. Senator Thad Cochran (R-Miss.), chairman of the Senate Appropriations Committee, met recently with representatives from the University of Mississippi Medical Center (UMMC) and its partners to discuss how sophisticated computer simulation models of the human body can aid the evaluation of pharmaceuticals and medical devices, reducing risk to patients and speeding approval of new cures and therapies.
The computer simulation model of the human body at UMMC, originally developed by the late Dr. Arthur Guyton, is one of the most advanced of its kind in the world. (http://bit.ly/2snc1mB)
Because of this expertise, UMMC has partnered with the U.S. Food and Drug Administration (FDA) as well as American and international healthcare interests to expand the use of simulated clinical trials both in the United States and the European Union. Cochran, as appropriations chairman, has included provisions in appropriations bills to promote the use of these “in silico” trials.
Those meeting with Cochran included: (left to right, seated) Dr. Adriano Henney, Secretary General, Avicenna Alliance, Brussels, Belgium; and Tina Morrison, Ph.D., FDA Modeling and Simulation Working Group chair; (standing) Carla Cartwright, Johnson & Johnson director of government affairs and policy; Ine Skottheim Rusten, Ph.D., European Medicines Agency Modeling and Simulation Working Group chair, Oslo, Norway; Markus Reiterer, Ph.D., Medtronic senior principal scientist, Minneapolis; Thierry Marchal, ANSYS global industry director for healthcare, construction & consumer products, Wavre, Belgium; James Kennedy, Avicenna Alliance Secretariat, Brussels; W. Andrew Pruett, Ph.D., UMMC Department of Physiology and Biophysics; Frank Weichold, M.D., Ph.D., FDA Director for Science and Innovation; Edward Magerrison, Ph.D., FDA Director of Office of Science and Engineering; and Paul Aguilar, FDA congressional affairs specialist.
